967 related articles for article (PubMed ID: 28826184)
1. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
[TBL] [Abstract][Full Text] [Related]
2. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
3. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer's disease.
Hok-A-Hin YS; Del Campo M; Boiten WA; Stoops E; Vanhooren M; Lemstra AW; van der Flier WM; Teunissen CE
J Neuroinflammation; 2023 May; 20(1):107. PubMed ID: 37147668
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
5. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
[TBL] [Abstract][Full Text] [Related]
7. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
[TBL] [Abstract][Full Text] [Related]
8. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
9. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
10. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
12. Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology.
Tautvydaitė D; Antonietti JP; Henry H; von Gunten A; Popp J
J Psychiatr Res; 2017 Jul; 90():12-20. PubMed ID: 28213293
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
Sierra-Rio A; Balasa M; Olives J; Antonell A; Iranzo A; Castellví M; Bosch B; Grau-Rivera O; Fernandez-Villullas G; Rami L; Lladó A; Sánchez-Valle R; Molinuevo JL
Neurodegener Dis; 2016; 16(1-2):69-76. PubMed ID: 26560503
[TBL] [Abstract][Full Text] [Related]
14. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
[TBL] [Abstract][Full Text] [Related]
15. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
16. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
19. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
20. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
